460 results on '"Kortüm, K."'
Search Results
2. Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence
3. Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma
4. Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
5. Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment
6. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma
7. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis
8. Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study
9. Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by 18F-FDG and 11C-methionine PET/CT
10. Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression
11. Whole-Body MRI with an Ultrahigh b-Value of 2000 s/mm2 Improves the Specificity of Diffusion-Weighted Imaging in Patients with Plasma Cell Dyscrasias
12. Auswirkungen einer stringenteren IVOM-Behandlungsorganisation auf die Anzahl der Behandlungen und Untersuchungen im Praxisalltag
13. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
14. Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study
15. Eng verknüpft : römische Villa und Fernstraße
16. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
17. COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan
18. Evaluation of patient satisfaction with an ophthalmology video consultation during the COVID-19 pandemic
19. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
20. Real‐world treatment patterns in patients initiating third‐line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.
21. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
22. Real‐world treatment patterns in patients initiating third‐line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain
23. Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma
24. Venetoclax salvage therapy in relapsed/refractory multiple myeloma
25. Evaluierung der Patientenzufriedenheit mit einer augenärztlichen Videosprechstunde während der COVID-19-Pandemie
26. MYC dysregulation in the progression of multiple myeloma
27. CXCR4-Directed Endoradiotherapy as New Treatment Option in Advanced Multiple Myeloma
28. Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
29. The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT
30. Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy
31. Spectrum and functional validation of PSMB5 mutations in multiple myeloma
32. Diagnostische und therapeutische Betrachtungen zum Rezidiv des multiplen Myeloms: Eine aktuelle Übersicht
33. P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA
34. P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
35. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
36. Supplement 2. Next generation sequencing results for first round screen from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
37. Data from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
38. Supplement 5. A total of 36 mutations in 19S proteasome subunits out of 895 patients were identified in CoMMpass study. from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
39. Figure S1 from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
40. Supplement 1. sgRNA sequences targeting PSMC1 to C6 from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
41. Supplement 3. sgRNA sequences used for second round screen. from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
42. FigureS2 from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
43. Supplemental Figure legends from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
44. Supplement 4. Next generation sequencing results for second round screen. from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
45. Table S1: IC50 (nM) for M cells deleted PSMC subunits treated with BTZ from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
46. Supplementary Table 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
47. Supplementary Figure 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
48. Supplementary Table 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
49. Supplementary Figure 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
50. Supplementary Figure 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.